she knew someone that worked at her place of employment that developed GBS after the COVID shot; Patient also was reported to have Long Covid; This is a spontaneous report received from a Pharmacist from a sales representative. A patient (age and gender not provided) received COVID-19 Vaccine – Manufacturer Unknown, as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient’s relevant medical history and concomitant medications were not reported. The following information was reported: POST-ACUTE COVID-19 SYNDROME (medically significant) with onset 2024, outcome “unknown”, described as “Patient also was reported to have Long Covid”; GUILLAIN-BARRE SYNDROME (medically significant) with onset 2024, outcome “unknown”, described as “she knew someone that worked at her place of employment that developed GBS after the COVID shot”. It was unknown if therapeutic measures were taken as a result of guillain-barre syndrome, post-acute covid-19 syndrome. Clinical course: It was reported that event happened approximately one year ago. She was unsure which COVID vaccine it was and unsure of the manufacturer (not known if Pfizer vaccine). Patient also was reported to have Long Covid. No other details provided. It was unknown if any treatment was received. It was unknown if patient received any other vaccines on the same date as the vaccine and unknown if the patient receive any other vaccines within 4 weeks PRIOR to the vaccine. It was unknown if the patient was taking any other medications within 2 weeks of the event starting. No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.; Sender’s Comments: As there is limited information in the case provided, the causal association between the events Guillain-Barre syndrome, and post-acute COVID-19 syndrome; and the suspect drug BNT162B2 cannot be excluded. The case will be reassessed once new information is available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.